Literature DB >> 12115337

Polymerase chain reaction-based diagnosis of bone marrow involvement in 170 cases of non-Hodgkin lymphoma.

Yoon Hee Kang1, Chan Jeoung Park, Eul Joo Seo, Jooryung Huh, Sung Bae Kim, Yoon-Koo Kang, Hyun Sook Chi.   

Abstract

BACKGROUND: Up to the current time, diagnosis of bone marrow (BM) involvement in non-Hodgkin lymphoma (NHL) has been based on morphologic findings. Polymerase chain reaction (PCR) for antigen receptor gene rearrangements has the potential to increase the detection sensitivity of minimal degrees of BM involvement. The authors therefore assessed PCR-based clonalities of BM concurrently with morphology from 170 cases with NHL and evaluated the usefulness of comparative analysis of clonalities between bilateral BMs and the lymph node and the clinical significance of PCR based clonalities of BM.
METHODS: Bilateral BM clot sections of 170 cases and 47 lymph nodes were tested for immunoglobulin heavy chain gene rearrangement or T-cell receptor gamma gene rearrangement according to the B- or T-lineage of the lymph node.
RESULTS: When compared with morphology, the results of PCR showed an unexpectedly low positive concordance rate of 61.0% for B-cell NHL and 57.1% for T-cell NHL. When the clonality of BM was compared with that of lymph nodes in B-cell NHL, bilateral clonalities of BM showed high concordance with the clonality of the lymph nodes. PCR-based clonality did not show significant impact on survival.
CONCLUSIONS: Morphology remains the gold standard in the evaluation of BM involvement by NHL. Although the comparative analysis of BM clonality and that of the lymph nodes is considered a valuable tool that increases the reliability of clonality, PCR-based clonality of BM does not significantly add to the sensitivity of diagnosing BM involvement by NHL. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115337     DOI: 10.1002/cncr.10584

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Splitting bone marrow trephines into frozen and fixed fragments allows parallel histological and molecular detection of B cell malignant infiltrates.

Authors:  M Parrens; N Carrere; K Bouabdallah; O Fitoussi; J-F Goussot; P Dubus; A de Mascarel; J-P Merlio
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

2.  Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells.

Authors:  Cristina Gattazzo; Antonella Teramo; Francesca Passeri; Elena De March; Samuela Carraro; Valentina Trimarco; Federica Frezzato; Tamara Berno; Gregorio Barilà; Veronica Martini; Francesco Piazza; Livio Trentin; Monica Facco; Gianpietro Semenzato; Renato Zambello
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

3.  Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.

Authors:  Ka-To Shum; Jiehua Zhou; John J Rossi
Journal:  J Cancer Ther       Date:  2013-06-01

4.  Prognostic value of bone marrow involvement by clonal immunoglobulin gene rearrangements in follicular lymphoma.

Authors:  Ellen Berget; Lars Helgeland; Knut Liseth; Turid Løkeland; Anders Molven; Olav Karsten Vintermyr
Journal:  J Clin Pathol       Date:  2014-09-18       Impact factor: 3.411

5.  Utility of an immunoglobulin gene rearrangement assay based on multiplex PCR in detecting bone marrow involvement in B-cell non-Hodgkin lymphoma.

Authors:  Dong Jin Park; Hyoun Chan Cho; Jung Hye Kwon; Ji-Young Park
Journal:  Blood Res       Date:  2017-06-22

6.  Increase of CD3+CD7- T cells in bone marrow predicts invasion in patients with T-cell non-Hodgkin's lymphoma.

Authors:  Ziyang Huang; Binbin Chen; Yixin Ling; Yangya Pan; Songfu Jiang; Shenghui Zhang; Kang Yu; Yixiang Han
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

7.  Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).

Authors:  Dipti Talaulikar; Bruce Shadbolt; Jane E Dahlstrom; Anne McDonald
Journal:  J Hematol Oncol       Date:  2009-11-22       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.